CSL posts FY profit above guidance

Group tips profit growth of 10% for current year despite economic headwinds.

Blood products and vaccine supplier CSL Ltd is tipping profit growth of 10% for the current year despite economic headwinds weighing on trading conditions, after posting a bumper full-year net profit. 

Investors were unimpressed by the news. At 1205 AEST shares in the company fell 2.76% to $65.93 against a benchmark index rise of 0.01%.

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles